Plasma angiopoietin‐1, angiopoietin‐2 and Tie‐2 in breast and prostate cancer: a comparison with VEGF and Flt‐1

Caine, Graham J.; Blann, AD; Stonelake, Paul S.; Ryan, Peter; Lip, Gregory Y.H.

doi:10.1046/j.1365-2362.2003.01243.x

Cited by 89 publications

(67 citation statements)

References 71 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are a few studies on serum Ang-1 levels, and these have reported conflicting results. Compared with the level in controls, the serum Ang-1 level was elevated in breast cancer [25] but lower in thyroid cancer [26]; the level was similar to the control level in prostate cancer [25] and acute myeloid leukemia [27].…”

Section: Introductionmentioning

confidence: 50%

“…In that report, thyroid cancer patients had lower serum Ang-1 and higher serum Ang-2 levels compared with controls, although the prognostic significance was not evaluated. However, an earlier study found variable serum Ang-1 levels according to different types of cancers [25]. In tissue studies, Ang-1 is upregulated in various malignancies, with a few exceptions [22,29,38].…”

Section: Discussionmentioning

confidence: 94%

“…The tissue expression level of Ang-2 is related to the stage progression and overall survival [23,24]. Serum Ang-2 has also been reported to be increased in breast cancer [25], prostate cancer [25], thyroid cancer [26], acute myeloid leukemia [27], and lung cancer [28], with prognostic implications in the latter two cancers.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

et al. 2009

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 50%

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

et al. 2009

View full text Add to dashboard Cite

“…We also confirm raised VEGF and vWf in this disease although we failed to find raised angiopoietin-2. [15][16][17] Notably, in the two control groups, HO-1 correlated with VEGF but in prostate cancer they failed to correlate. Despite considerable animal data, wherein there are indications of various roles of HO-1 in cancer and cardiovascular disease, the role of HO-1 in actual human disease is unclear.…”

Section: Discussionmentioning

confidence: 91%

“…We tested our hypotheses in a simple cross-sectional case-control study of early prostate cancer as this disease is known to be associated with raised markers of angiogenesis and endothelial damage/dysfunction. [15][16][17] …”

Section: Introductionmentioning

confidence: 99%

Increased levels of plasma haemoxygenase-1 in prostate cancer

Blann

Balakrishnan

Ryan

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Angiogenesis, a key component of cancer, may be driven by angiogenic growth factors, such as vascular endothelial growth factor (VEGF) and angiopoietin-2. Haemoxygenase-1 (HO-1), a haemdegrading enzyme, may have alternative roles in angiogenesis. Levels of plasma HO-1 have not been reported in prostate cancer. We tested the hypothesis of abnormal HO-1 in 30 men with early prostate cancer, compared with 22 men with benign prostate disease (BPD) and 26 men free of prostate disease, and that HO-1 levels would correlate with VEGF, angiopoietin-2, von Willebrand factor (vWf, marking endothelial perturbation) and PSA. Plasma HO-1 was twofold higher in prostate cancer than in the two control groups, while vWf, VEGF and PSA were also raised (all Po0.02). In the subjects free of prostate disease and in the BPD groups, HO-1 correlated significantly with VEGF (r40.5, Po0.02) but the correlation in prostate cancer was not significant (r ¼ 0.117, P ¼ 0.537). There were no correlations with PSA or the Gleason stage. We conclude that HO-1 is associated with VEGF in health and BPD, but in the presence of prostate cancer, raised levels of both HO-1 and VEGF fail to correlate. This observation may have implications for the pathogenesis of prostate cancer.

show abstract

Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma

Ozawa

Yao

Chanthery

et al. 2005

Cancer

View full text Add to dashboard Cite

Percutaneous pulmonary valve perforation in selected neonates with pulmonary valve atresia and intact ventricular septum has been well established as a therapeutic option. Pulmonary valve perforation is associated with significant risks including perforation of the right ventricle. Optimal catheter positioning is crucial to the success of the procedure. This report describes a novel technique for accurate positioning of a guiding catheter during perforation of an atretic pulmonary valve. © 2008 Wiley‐Liss, Inc.

show abstract

Plasma angiopoietin‐1, angiopoietin‐2 and Tie‐2 in breast and prostate cancer: a comparison with VEGF and Flt‐1

Abstract: Abnormal levels of Ang-1, Ang-2 and their receptor, Tie-2, are present in breast and prostate cancer, and their interrelationships may be important in the pathophysiology of these conditions.

Cited by 89 publications

References 71 publications

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

Increased levels of plasma haemoxygenase-1 in prostate cancer

Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma

Contact Info

Product

Resources

About